- The FDA approves Grifols (NASDAQ:GRFS)(OTCPK:GIKLY) Erytra Eflexis, an automated benchtop analyzer for pretransfusion compatibility testing. The company says the approval is the third in the U.S. for its blood typing portfolio.
FDA OKs Grifols Erytra Elfexis analyzer
Recommended For You
More Trending News
About GRFS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
GRFS | - | - |
Grifols, S.A. |